{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-088391","form_type":"8-K","ticker":"CRDF","cik":"0001213037","company_name":"Cardiff Oncology, Inc.","filed_at":"2023-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.344093+00:00","generated_at":"2026-06-12T03:47:59.949552+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Cardiff Oncology to Advance Onvansertib to First-Line mCRC, Partners with Pfizer Ignite for New Trial","bullets":["Announces new lead program in first-line RAS-mutated metastatic colorectal cancer with FDA agreement.","Launches CRDF-004 Phase 2 trial with 90 patients; interim topline results expected mid-2024.","Pfizer Ignite will support clinical execution; expands relationship from Pfizer's 2021 equity investment.","Discontinues ONSEMBLE second-line trial to focus resources on first-line program.","Cash position of $89.4M as of June 30, 2023, sufficient to fund operations into 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-088391","json":"https://secwatch.observer/filing/0001104659-23-088391.json","markdown":"https://secwatch.observer/filing/0001104659-23-088391.md","text":"https://secwatch.observer/filing/0001104659-23-088391.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213037/000110465923088391/0001104659-23-088391-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213037/000110465923088391/tm2322922d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T03:47:59.949552+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}